Comprehensive Perspective Towards the Management of Proteinopathies by Elucidating Protein Misfolding and Aggregation
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Protein misfolding and aggregation is the phenomenon of the generic propensity of proteins, considered as a dark side of the protein world, and its exact mechanism is still not deciphered. Understanding the complexity of protein aggregation is currently the primary apprehension and challenge in biology and medicine due to their association with various debilitating human proteinopathies and neurodegenerative diseases. The mechanism of protein aggregation, associated diseases, and the development of efficient therapeutic strategies against these diseases are very challenging. These diseases are caused by different proteins, each protein with different mechanisms and consisting of various microscopic phases or events. These microscopic steps are functioning on different timescales during aggregation. Here, we highlighted the different features and current trends in protein aggregation. The study thoroughly recapitulates the various factors influencing, possible causes, types of aggregates and aggregation, their different proposed mechanisms, and the methods used to study the aggregation. Additionally, the formation and elimination of misfolded or aggregated proteins in the cell, the role of the ruggedness of the protein folding landscape in protein aggregation, proteinopathies, and the challenges for their prevention are comprehensively elucidated. A holistic understanding of different aspects of aggregation, molecular steps governing the various features of protein quality control, and crucial queries about the modulation of these processes and their interactions with other systems in cellular protein quality control can be considered conducive to comprehending the mechanism, designing effective approaches towards prevention of protein aggregation, rationalizing the etiology and development of novel strategies against therapy and management of the proteinopathies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - 23(2023), 2 vom: 01., Seite 153-180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahanger, Ishfaq Ahmad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Generic propensity |
|---|
| Anmerkungen: |
Date Revised 13.10.2023 published: Print Citation Status Publisher |
|---|
| doi: |
10.2174/1871527322666230306085937 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353826995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353826995 | ||
| 003 | DE-627 | ||
| 005 | 20231226060915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527322666230306085937 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353826995 | ||
| 035 | |a (NLM)36876837 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahanger, Ishfaq Ahmad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comprehensive Perspective Towards the Management of Proteinopathies by Elucidating Protein Misfolding and Aggregation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Protein misfolding and aggregation is the phenomenon of the generic propensity of proteins, considered as a dark side of the protein world, and its exact mechanism is still not deciphered. Understanding the complexity of protein aggregation is currently the primary apprehension and challenge in biology and medicine due to their association with various debilitating human proteinopathies and neurodegenerative diseases. The mechanism of protein aggregation, associated diseases, and the development of efficient therapeutic strategies against these diseases are very challenging. These diseases are caused by different proteins, each protein with different mechanisms and consisting of various microscopic phases or events. These microscopic steps are functioning on different timescales during aggregation. Here, we highlighted the different features and current trends in protein aggregation. The study thoroughly recapitulates the various factors influencing, possible causes, types of aggregates and aggregation, their different proposed mechanisms, and the methods used to study the aggregation. Additionally, the formation and elimination of misfolded or aggregated proteins in the cell, the role of the ruggedness of the protein folding landscape in protein aggregation, proteinopathies, and the challenges for their prevention are comprehensively elucidated. A holistic understanding of different aspects of aggregation, molecular steps governing the various features of protein quality control, and crucial queries about the modulation of these processes and their interactions with other systems in cellular protein quality control can be considered conducive to comprehending the mechanism, designing effective approaches towards prevention of protein aggregation, rationalizing the etiology and development of novel strategies against therapy and management of the proteinopathies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Protein aggregation | |
| 650 | 4 | |a generic propensity | |
| 650 | 4 | |a neurodegenerative diseases | |
| 650 | 4 | |a protein folding landscape | |
| 650 | 4 | |a protein quality control | |
| 650 | 4 | |a proteinopathies | |
| 700 | 1 | |a Ashraf, Ghulam Md |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Anurag |e verfasserin |4 aut | |
| 700 | 1 | |a Islam, Asimul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g 23(2023), 2 vom: 01., Seite 153-180 |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:2 |g day:01 |g pages:153-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527322666230306085937 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 2 |b 01 |h 153-180 | ||